

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR GROUP

1. Incorporation

Our Company was established under the laws of the PRC as a limited liability company on May 25, 2004. On January 22, 2026, our Company was converted to a joint stock company with limited liability under the PRC Company Law. The registered address of our Company in the PRC is on Room 1002, Building 2, West Zone of Wanjing Hupan Center, Qiantang District, Hangzhou, Zhejiang Province, PRC.

We have established a place of business in Hong Kong at 46/F, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, and have submitted an application to the Companies Registry in Hong Kong as a non-Hong Kong company under Part 16 of the Companies Ordinance. Ms. Ho Wing Nga has been appointed as the authorised representative of our Company for the acceptance of service of process and notice in Hong Kong. The address for service of process on our Company in Hong Kong is the same as our principal place of business in Hong Kong as set out above.

As our Company was established in the PRC, we are subject to the relevant laws and regulations of the PRC. An overview of the relevant aspects of laws and regulations of the PRC is set out in “Regulatory Overview” in this document. A summary of our Articles of Association is set out in Appendix V to this document.

2. Changes in Share Capital of our Company

See the sections headed “History, Development and Corporate Structure — Development and Major Shareholding Changes of the Company” and “History, Development and Corporate Structure — Pre-[REDACTED] Investments” of this document for details of the alteration in our share capital within the two years immediately preceding the date of this document. Save as disclosed above, there has been no alteration in the share capital within two years immediately preceding the date of this document.

3. Changes in the Share Capital of Our Subsidiaries

The list of our subsidiaries is set out in Note 1 to the Accountants’ Report, the text of which is set out in Appendix I to this document. Save as disclosed below, there has been no alteration in the share capital of any of our subsidiaries within the two years preceding the date of this document.

Guangdong Weilin

On December 22, 2025, the registered share capital of Guangdong Weilin increased from RMB5.0 million to RMB30.0 million.

On July 21, 2026, the registered share capital of Guangdong Weilin increased from RMB30.0 million to RMB50.0 million.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

4. Resolutions of our Shareholders in relation to the [REDACTED]

Pursuant to the resolutions passed at a duly convened general meeting of our Shareholders on February 11, 2026, the following resolutions, among others, were duly passed:

- (a) the sub-division of the Shares with nominal value of RMB1.0 each on the basis of 1:10, effective immediately prior to the [REDACTED], and taking into account the Share Subdivision, the issuance by our Company of H Shares of nominal value of RMB0.10 each and such H Shares to be [REDACTED] on the [REDACTED];
- (b) the number of H Shares to be issued pursuant to the [REDACTED], and the grant to the [REDACTED] of the [REDACTED] of not more than [REDACTED]% of the number of H Shares issued pursuant to the [REDACTED];
- (c) the [REDACTED] from the [REDACTED] shall be applied for the purposes disclosed in “Future Plans and [REDACTED]” of this document;
- (d) subject to the CSRC’s approval, upon completion of the Share Subdivision and the [REDACTED], [REDACTED] Unlisted Shares in aggregate of our Company will be converted into H Shares;
- (e) subject to the completion of the [REDACTED], the conditional adoption of the Articles of Association which shall become effective upon the [REDACTED]; and
- (f) authorisation of our Board or/and its authorised persons to handle all matters relating to, among other things, the [REDACTED] and the [REDACTED].

5. Restrictions on Repurchase

For details of the restrictions on share repurchases by our Company, see “Appendix V — Summary of the Articles of Association” of this document.

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contracts

The following contract (not being contracts entered into in the ordinary course of business) has been entered into by us within the two years preceding the date of this document and are or may be material:

- (a) [REDACTED];
- (b) Share Transfer Agreement regarding the acquisition of Guangdong Weilin between our Company and Mr. Zhao dated October 28, 2025;
- (c) Share Transfer Agreement regarding the acquisition of Guangdong Weilin between our Company and Shanghai Yilian Enterprise Management Center (Limited Partnership) (上海毅聯企業管理中心(有限合夥)), dated October 28, 2025; and
- (d) Share Transfer Agreement regarding the acquisition of Guangdong Weilin between our Company and Shanghai Yiguang Enterprise Management Center (Limited Partnership) (上海毅光企業管理中心(有限合夥)), dated October 28, 2025.

APPENDIX VI STATUTORY AND GENERAL INFORMATION

2. Intellectual Property Rights of Our Group

(a) Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Place of Registration	Registered Owner	Class	Registration Number	Expiry Date
1 . . .	PANACRO	PRC	Our Company	5	21877690	February 13, 2028
2 . . .	PANACRO	PRC	Our Company	10	21877881	December 27, 2027
3 . . .	PANACRO	PRC	Our Company	42	21877931	December 27, 2027
4 . . .	PANACRO	PRC	Our Company	44	21877831	December 27, 2027
5 . . .		PRC	Our Company	10	21877906A	January 13, 2028
6 . . .		PRC	Our Company	42	21877913A	January 27, 2028
7 . . .		PRC	Our Company	44	21877959	December 27, 2027
8 . . .		PRC	Our Company	42	21877913	October 27, 2028
9 . . .	博纳西亚	PRC	Our Company	5	21877826	December 27, 2027
10 . . .	博纳西亚	PRC	Our Company	10	21877747	December 27, 2027
11 . . .	博纳西亚	PRC	Our Company	42	21877902	December 27, 2027
12 . . .	博纳西亚	PRC	Our Company	44	21878010	December 27, 2027
13 . . .	威 临	PRC	Suzhou Panacro	42	51290579	July 13, 2031
14 . . .	WeLinc 威 临	PRC	Suzhou Panacro	42	46550657	December 13, 2031

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registered Owner	Class	Registration Number	Expiry Date
15 . . .		PRC	Guangdong Weilin	45	71414988	January 20, 2034

(b) Copyrights

As of the Latest Practicable Date, we were the registered owner of and had the right to use the following copyrights which we consider to be or may be material to our business:

No.	Name of Copyright	Place of Registration	Registered Owner	Registration Number	Registration Date
1 . . .	博納臨床試驗CAPA管理系統V1.0 (Panacro Clinical Trial CAPA Management System V1.0)	PRC	Our Company	2025SR1233228	July 11, 2025
2 . . .	博納臨床試驗GCP培訓證書管理系統 V1.0 (Panacro Clinical Trial GCP Training Certificate Management System V1.0)	PRC	Our Company	2025SR1236289	July 11, 2025
3 . . .	博納臨床試驗多平台SOP培訓系統 V1.1 (Panacro Clinical Trial Multi-Platform SOP Training System V1.1)	PRC	Our Company	2025SR1236728	July 11, 2025
4 . . .	博納臨床試驗項目質量溯源系統V1.0 (Panacro Clinical Trial Project Quality Traceability System V1.0)	PRC	Our Company	2025SR1233173	July 11, 2025
5 . . .	臨床試驗CRO智能數據治理平台V1.0 (Clinical Trial CRO Intelligent Data Governance Platform V1.0)	PRC	Our Company	2025SR1238148	July 11, 2025
6 . . .	臨床試驗項目核算管理系統V1.0 (Clinical Trial Project Accounting Management System V1.0)	PRC	Our Company	2025SR1234472	July 11, 2025
7 . . .	臨床試驗報表生成系統V1.0 (Clinical Trials Report Generation System V1.0)	PRC	Our Company	2024SR0557614	April 24, 2024
8 . . .	博納臨床試驗項目中心物資管理系統 V1.0 (Panacro Clinical Trial Project Centralised Materials Management System V1.0)	PRC	Our Company	2024SR1600562	October 24, 2024

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration Number	Registration Date
9 . . .	博納臨床試驗項目SOP模板配置系統 V1.0 (Panacro Clinical Trial Project SOP Template Configuration System V1.0)	PRC	Our Company	2024SR1594448	October 23, 2024
10 . . .	博納臨床試驗項目方案偏離管理系統 V1.0 (Panacro Clinical Trial Project Deviation Management System V1.0)	PRC	Our Company	2024SR1214164	August 20, 2024
11 . . .	博納臨床試驗項目里程碑進度管理系 統V1.0 (Panacro Clinical Trial Project Milestone Progress Management System V1.0)	PRC	Our Company	2024SR1210332	August 20, 2024
12 . . .	博納臨床試驗項目樣本管理系統V1.0 (Panacro Clinical Trial Project Sample Management System V1.0)	PRC	Our Company	2024SR1210342	August 20, 2024
13 . . .	臨床試驗監查報告在線撰寫系統V1.0 (Clinical Trial Monitoring Report Online Authoring System V1.0)	PRC	Our Company	2024SR0645380	May 14, 2024
14 . . .	臨床試驗受試者入組趨勢分析系統 V1.0 (Clinical Trial Subject Enrolment Trend Analysis System V1.0)	PRC	Our Company	2023SR1602489	December 11, 2023
15 . . .	藥物臨床試驗PD記錄系統V1.0 (Drug Clinical Trial PD Recording System V1.0)	PRC	Our Company	2023SR1100409	September 19, 2023
16 . . .	藥物臨床試驗SSU快啟系統V1.0 (Drug Clinical Trial SSU Rapid Initiation System V1.0)	PRC	Our Company	2023SR1098663	September 19, 2023
17 . . .	藥物臨床試驗項目智能報價管理系統 V1.0 (Drug Clinical Trial Project Intelligent Quotation Management System V1.0)	PRC	Our Company	2023SR1092307	September 18, 2023
18 . . .	藥物臨床試驗預算管理系統V1.0 (Drug Clinical Trial Budget Management System V1.0)	PRC	Our Company	2023SR1091994	September 18, 2023
19 . . .	臨床實驗數據採集管理系統 V1.0 (Clinical Trial Data Collection Management System V1.0)	PRC	Our Company	2022SR0089148	January 13, 2022
20 . . .	臨床試驗數據統計分析系統 V1. 0 (Clinical Trial Data Statistical Analysis System V1.0)	PRC	Our Company	2022SR0088887	January 13, 2022

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration Number	Registration Date
21 . . .	臨床試驗大數據信息化服務平台V1.0 (Clinical Trial Big Data Informatisation Service Platform V1.0)	PRC	Our Company	2022SR0088888	January 13, 2022
22 . . .	臨床試驗大數據可視化服務平台V1.0	PRC	Our Company	2022SR0088889	January 13, 2022
23 . . .	臨床試驗數據驗證系統V1.0 (Clinical Trial Data Validation System V1.0)	PRC	Our Company	2022SR0083867	January 12, 2022
24 . . .	銀屑病臨床試驗受試者招募系統V1.0 (Psoriasis Clinical Trial Subject Recruitment System V1.0)	PRC	Our Company	2021SR1885426	November 25, 2021
25 . . .	臨床試驗監查員調度系統 V1.0 (Clinical Trial Monitor Dispatch System V1.0)	PRC	Our Company	2021SR1885471	November 25, 2021
26 . . .	臨床試驗稽查問題跟蹤系統 V1. 0 (Clinical Trial Audit Issue Tracking System V1.0)	PRC	Our Company	2021SR1885470	November 25, 2021
27 . . .	臨床試驗進度監控系統 V1.0 (Clinical Trial Progress Monitoring System V1.0)	PRC	Our Company	2021SR1885472	November 25, 2021
28 . . .	臨床試驗研究中心篩選系統 V1.0 (Clinical Trial Research Centre Screening System V1.0)	PRC	Our Company	2021SR1885451	November 25, 2021
29 . . .	臨床試驗數據統計分析監控系統V1.0 (Clinical Trial Data Statistical Analysis Monitoring System V1.0)	PRC	Our Company	2021SR1885450	November 25, 2021
30 . . .	腫瘤臨床試驗監控信息化管理系統 V1.0 (Clinical Oncology Trial Monitoring Information Management System V1.0)	PRC	Our Company	2021SR1885448	November 25, 2021
31 . . .	臨床試驗受試者訪視管理系統 V1.0 (Clinical Trial Subject Visit Management System V1.0)	PRC	Our Company	2021SR1781391	November 18, 2021
32 . . .	臨床試驗受試者入組監控系統 V1.0 (Clinical Trial Subject Enrolment Monitoring System V1.0)	PRC	Our Company	2021SR1781390	November 18, 2021
33 . . .	臨床試驗受試者智能篩選系統 V1.0 (Clinical Trial Subject Intelligent Screening System V1.0)	PRC	Our Company	2021SR1781301	November 18, 2021
34 . . .	臨床試驗電子病歷管理系統 V1. 0 (Clinical Trial Electronic Medical Record Management System V1.0)	PRC	Our Company	2021SR1939009	November 30, 2021

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration Number	Registration Date
35 . . .	藥物臨床試驗項目合同管理系統V1.0 (Drug Clinical Trial Project Contract Management System V1.0)	PRC	Beijing Panacro	2019SR0042897	January 14, 2019
36 . . .	藥物臨床試驗人員管理系統V1.0 (Drug Clinical Trial Personnel Management System V1.0)	PRC	Beijing Panacro	2019SR0037917	January 11, 2019
37 . . .	藥物臨床試驗項目文檔管理系統V1.0 (Clinical Trial Project Documentation Management System V1.0)	PRC	Beijing Panacro	2019SR0017584	January 7, 2019
38 . . .	藥物臨床試驗工時管理系統V1.0 (Clinical Trial Time Management System V1.0)	PRC	Beijing Panacro	2019SR0018097	January 7, 2019
39 . . .	藥物臨床試驗SOP管理系統V1.0 (Clinical Trial SOP Management System V1.0)	PRC	Beijing Panacro	2019SR0015218	January 4, 2019
40 . . .	藥物臨床試驗在線培訓考試管理系統V1.0 (Clinical Trial Online Training and Examination Management System V1.0)	PRC	Beijing Panacro	2019SR0015225	January 4, 2019
41 . . .	藥物臨床試驗質量管理評價系統V1.0 (Clinical Trial Quality Management Evaluation System V1.0)	PRC	Beijing Panacro	2015SR189173	September 29, 2015
42 . . .	臨床試驗數據管理與統計分析軟件V1.0 (Clinical Trial Data Management and Statistical Analysis Software V1.0)	PRC	Beijing Panacro	2015SR189178	September 29, 2015
43 . . .	新藥研發過程信息服務系統V1.0 (New Drug Development Process Information Service System V1.0)	PRC	Beijing Panacro	2015SR189182	September 29, 2015
44 . . .	生物統計軟件V1.0 (Biostatistics Software V1.0)	PRC	Beijing Panacro	2015SR189185	September 29, 2015
45 . . .	醫療器械臨床試驗評價系統V1.0 (Medical Device Clinical Trial Evaluation System V1.0)	PRC	Beijing Panacro	2015SR189189	September 29, 2015
46 . . .	註冊事務管理系統V1.0 (Registration Affairs Management System V1.0)	PRC	Beijing Panacro	2015SR189192	September 29, 2015
47 . . .	博納臨床試驗數據驗證系統V1.0 (Panacro Clinical Trial Data Verification System V1.0)	PRC	Suzhou Panacro	2021SR2196417	December 28, 2021

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration Number	Registration Date
48 . . .	博納臨床試驗數據採集管理系統V1.0 (Panacro Clinical Trial Data Collection Management System V1.0)	PRC	Suzhou Panacro	2021SR2196416	December 28, 2021
49 . . .	博納臨床試驗數據統計分析系統V10 (Panacro Clinical Trial Data Statistical Analysis System V10)	PRC	Suzhou Panacro	2021SR2194889	December 28, 2021
50 . . .	疫苗臨床試驗受試者招募系統V1.0 (Vaccine Clinical Trial Subject Recruitment System V1.0)	PRC	Suzhou Panacro	2022SR1627656	December 29, 2022
51 . . .	疫苗臨床試驗數據統計分析監控系統 V1.0 (Vaccine Clinical Trial Data Statistical Analysis Monitoring System V1.0)	PRC	Suzhou Panacro	2022SR1627657	December 29, 2022
52 . . .	疫苗臨床試驗項目管理系統V1.0 (Vaccine Clinical Trial Project Management System V1.0)	PRC	Suzhou Panacro	2022SR1627877	December 29, 2022
53 . . .	疫苗臨床試驗大數據可視化服務平台 V1.0 (Vaccine Clinical Trial Big Data Visualisation Service Platform V1.0)	PRC	Suzhou Panacro	2022SR1623416	December 28, 2022
54 . . .	疫苗藥物臨床試驗項目合同管理系統 V1.0 (Vaccine Drug Clinical Trial Project Contract Management System V1.0)	PRC	Suzhou Panacro	2022SR1623417	December 28, 2022
55 . . .	疫苗臨床試驗項目核算發布系統V1.0 (Vaccine Clinical Trial Project Accounting and Release System V1.0)	PRC	Suzhou Panacro	2022SR1623420	December 28, 2022
56 . . .	疫苗臨床試驗研究中心篩選系統V1.0 (Vaccine Clinical Trial Research Centre Screening System V1.0)	PRC	Suzhou Panacro	2022SR1619004	December 28, 2022
57 . . .	疫苗臨床試驗受試者入組監控系統 V1.0 (Vaccine Clinical Trial Subject Enrolment Monitoring System V1.0)	PRC	Suzhou Panacro	2022SR1615574	December 26, 2022
58 . . .	疫苗臨床試驗CRA監察系統V1.0 (Vaccine Clinical Trial CRA Monitoring System V1.0)	PRC	Suzhou Panacro	2022SR1615590	December 26, 2022
59 . . .	疫苗臨床試驗SSU快速啟動系統V1.0 (Vaccine Clinical Trial SSU Rapid Start-up System V1.0)	PRC	Suzhou Panacro	2022SR1615179	December 26, 2022

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration Number	Registration Date
60 . . .	疫苗臨床試驗進度監控系統V1.0 (Vaccine Clinical Trial Progress Monitoring System V1.0)	PRC	Suzhou Panacro	2022SR1615582	December 26, 2022
61 . . .	疫苗臨床試驗受試者智能篩選系統 V1.0 (Vaccine Clinical Trial Subject Intelligent Screening System V1.0)	PRC	Suzhou Panacro	2022SR1615589	December 26, 2022
62 . . .	數據傳輸及光盤準備管理系統V1.0 (Data Transfer and CD Preparation Management System V1.0)	PRC	Beijing Linzhi	2021SR0599458	April 26, 2021
63 . . .	總結報告審核管理系統V1.0 (Summary Report Review Management System V1.0)	PRC	Beijing Linzhi	2021SR0598372	April 26, 2021
64 . . .	文件存檔管理系統V1.0 (Document Archiving Management System V1.0)	PRC	Beijing Linzhi	2021SR0598260	April 26, 2021
65 . . .	中心實驗室數據傳輸文檔制定管理系統V1.0 (Central Laboratory Data Transfer Document Development Management System V1.0)	PRC	Beijing Linzhi	2021SR0598261	April 26, 2021
66 . . .	人工核査程序配置管理系統V1.0 (Manual Verification Procedure Configuration Management System V1.0)	PRC	Beijing Linzhi	2021SR0589599	April 25, 2021
67 . . .	統計分析圖標清單模板管理系統V1.0 (Statistical Analysis Chart Template Management System V1.0)	PRC	Beijing Linzhi	2021SR0589598	April 25, 2021
68 . . .	數據項目管理系統V1.0 (Data Item Management System V1.0)	PRC	Beijing Linzhi	2021SR0589597	April 25, 2021
69 . . .	編程記錄管理系統V1.0 (Programming Record Management System V1.0)	PRC	Beijing Linzhi	2021SR0589600	April 25, 2021
70 . . .	臨床試驗分析培訓管理平台V1.0 (Clinical Trial Analysis Training Management Platform V1.0)	PRC	Beijing Aismore	2017SR168073	May 9, 2017
71 . . .	臨床研究試驗預算管理系統V1.0 (Clinical Research Trial Budget Management System V1.0)	PRC	Beijing Aismore	2017SR168076	May 9, 2017
72 . . .	臨床研究內部稽查管理系統V1.0 (Clinical Research Internal Audit Management System V1.0)	PRC	Beijing Aismore	2017SR167990	May 9, 2017

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration Number	Registration Date
73 . . .	臨床試驗研究管控系統V1.0 (Clinical Trial Research Control System PRC V1.0)	PRC	Beijing Aismore	2017SR168069	May 9, 2017
74 . . .	臨床試驗檔案信息化管理軟件V1.0 (Clinical Trial Documentation Information Management Software V1.0)	PRC	Beijing Aismore	2017SR168081	May 9, 2017
75 . . .	CRC臨床服務管理軟件V1.0 (CRC Clinical Service Management Software V1.0)	PRC	Beijing Aismore	2017SR168085	May 9, 2017
76 . . .	藥物臨床試驗流程管理軟件V1.0 (Drug Clinical Trial Process Management Software V1.0)	PRC	Beijing Aismore	2016SR241721	August 31, 2016
77 . . .	臨床研究信息採集管理系統V1.0 (Clinical Research Information Collection Management System V1.0)	PRC	Beijing Aismore	2016SR243448	August 31, 2016
78 . . .	臨床試驗機構項目管理系統V1.0 (Clinical Trial Organisation Project Management System V1.0)	PRC	Beijing Aismore	2016SR241725	August 31, 2016
79 . . .	臨床研究項目綜合檢驗管理系統V1.0 (Clinical Research Project Comprehensive Inspection Management System V1.0)	PRC	Beijing Aismore	2016SR241729	August 31, 2016
80 . . .	藥品諮詢及用藥安全監測軟件V1.0 (Drug Consultation and Medication Safety Monitoring Software V1.0)	PRC	Beijing Aismore	2016SR241733	August 31, 2016
81 . . .	臨床數據統計分析管理軟件 V1.0 (Clinical Data Statistical Analysis Management Software V1.0)	PRC	Beijing Aismore	2016SR243453	August 31, 2016
82 . . .	GCP藥房管理系統V1.0 (GCP Pharmacy Management System V1.0)	PRC	Guangdong Weilin	2022SR1590895	December 20, 2022
83 . . .	臨床試驗遠程監查系統V1.0 (Clinical Trial Remote Monitoring System V1.0)	PRC	Guangdong Weilin	2022SR1590896	December 20, 2022
84 . . .	生物樣本管理系統V1.0 (Biological Sample Management System V1.0)	PRC	Guangdong Weilin	2022SR1591747	December 20, 2022
85 . . .	臨床試驗信息系統V1.0 (Clinical Trial Information System V1.0)	PRC	Guangdong Weilin	2022SR1590897	December 20, 2022

APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration Number	Registration Date
86 . . .	臨床試驗項目管理系統(CTMS) V2.1.0 (Clinical Trial Project Management System (CTMS) V2.1.0)	PRC	Guangdong Weilin	2022SR0836428	June 23, 2022
87 . . .	臨床研究文檔管理系統V1.0.3 (Clinical Research Document Management System V1.0.3)	PRC	Guangdong Weilin	2022SR0828021	June 23, 2022
88 . . .	臨床試驗電子數據採集系統V1.5 (Clinical Trial Electronic Data Capture System V1.5)	PRC	Guangdong Weilin	2022SR0834898	June 23, 2022
89 . . .	受試者管理平台 (SMP) V1.0 (Subject Management Platform (SMP) V1.0)	PRC	Guangdong Weilin	2022SR0835752	June 23, 2022
90 . . .	機構倫理系統 (GCPEC) V1.0 (Institutional Ethics System (GCPEC) V1.0)	PRC	Guangdong Weilin	2022SR0835751	June 23, 2022
91 . . .	博納臨床試驗項目藥品管理系統V1.0 (Panacro IMP Management System V1.0)	PRC	Our Company	2024SR1564462	October 21, 2024

(c) Domain Names

As of the Latest Practicable Date, we had registered and maintained ownership to the following domain names in the PRC which we consider to be or may be material to our business:

No.	Domain Name	Registered Owner	Filing date
1 . . .	panacro.com	Our Company	December 9, 2025
2 . . .	weilinct.com	Guangdong Weilin	October 18, 2024
3 . . .	bnxycro.com	Our Company	April 15, 2026

Save as disclosed above, as of the Latest Practicable Date, there were no other patents, trade or service marks, intellectual or industrial property rights which are or may be material in relation to our business.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

C. FURTHER INFORMATION ABOUT OUR DIRECTORS, CHIEF EXECUTIVE AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of Interest of Directors and Chief Executive

Disclosure of Interests

To the best knowledge of our Directors, saved as disclosed below, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised), none of our Directors or chief executive has any interests or short positions in the Shares, underlying Shares and debentures of our Company or any associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules.

Name of Shareholder	Nature of interest	Type of Shares	Shares held as of the Latest Practicable Date and immediately prior to the [REDACTED]		Shares held in the total share capital of our Company immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised)	
			Number of Shares ⁽¹⁾	Shareholding percentage (Approximate %) ⁽²⁾	Number of Shares ⁽¹⁾	Shareholding percentage (Approximate %) ⁽³⁾
Mr. Zhao ⁽⁴⁾⁽⁵⁾	Beneficial owner	Unlisted Shares	67,683,480	57.28%	[REDACTED]	[REDACTED]
	Beneficial owner	H Shares	–	–	[REDACTED]	[REDACTED]%
	Interest held by controlled corporation	Unlisted Shares	20,000,000	16.93%	[REDACTED]	[REDACTED]
	Interest held by controlled corporation	H Shares	–	–	[REDACTED]	[REDACTED]%

Notes:

- (1) All the interests stated are long positions.
- (2) The calculation is based on the total number of [REDACTED] Shares in issue as of the Latest Practicable Date taking into account the Share Subdivision.
- (3) The calculation is based on the assumption that (i) the Share Subdivision is completed; (ii) the [REDACTED] is not exercised; (iii) the [REDACTED] Unlisted Shares (taking into account the Share Subdivision) will be converted into H Shares; and (iv) the total number of the Shares in issue will be [REDACTED] immediately following the completion of the [REDACTED].
- (4) As of the Latest Practicable Date, Mr. Zhao was the executive and general partner of Boda Innovation, our Employee Incentive Platform established as a limited partnership. By virtue of the SFO, Mr. Zhao is deemed to be interested in the 15,000,000 Shares held by Boda Innovation.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (5) As of the Latest Practicable Date, Mr. Zhao was the executive and general partner of Bohua Innovation, our Employee Incentive Platform established as a limited partnership. By virtue of the SFO, Mr. Zhao is deemed to be interested in the 5,000,000 Shares held by Bohua Innovation.

Particulars of Service Contracts

Pursuant to Rules 19A.54 and 19A.55 of the Listing Rules, our Company [has entered into] a service agreement with each of the Directors which contains provisions in relation to, among other things, compliance of relevant laws and regulations, observations of Articles of Association and provisions on arbitration.

The principal particulars of these service agreements are: (a) each of the agreements is for a term of three years following his/her respective effective date of his/her appointment; (b) each of the agreements is subject to termination in accordance with their respective terms.

Save as disclosed above, our Company has not entered, and does not propose to enter, into any service contracts with any of the Directors in their respective capacities as Directors (other than contracts expiring or determinable by the employer within one year without the payment of compensation (other than statutory compensation)).

Directors’ Remuneration

For details of the Directors’ remuneration, see “Directors and Senior Management — Compensation of Directors and Senior Management.” and Note 8 to the Accountants’ Report as set out in Appendix I.

2. Disclosure of Interest of Substantial Shareholders

Interests in the Shares of our Company

Save as disclosed in the section headed “Substantial Shareholders” in this document, as of the Latest Practicable Date, our Directors were not aware of any persons who would, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised), having or be deemed or taken to the beneficial interests or short position in our Shares or underlying Shares which would fall to be disclosed to our Company under the provisions of 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the issued voting shares of our Company.

Interests in our Company’s subsidiaries

Immediately following the completion of the [REDACTED], all member companies of our Group (other than our Company) are wholly owned by our Company. As such, no person (other than our Company) will be interested, directly or indirectly, in 10% or more of share capital with the right to, in any event, vote at the general meeting of any other member (other than our Company) of our Group.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Disclaimers

Save as disclosed in the “History, Development and Corporate Structure” section, none of our Directors or any of the parties listed in “— Other Information — Consents of Experts” in this appendix is interested in our promotion, or in any assets which, within the two years immediately preceding the date of this document, have been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to our Company; or

Saved as disclosed in the “Underwriting” section, none of our Directors is materially interested in any contract or arrangement subsisting at the date of this document that is significant in relation to our business.

D. SHARE INCENTIVE SCHEMES

In recognition of the contributions of, the employees of our Group, and to incentivize them to further promote our development, we adopted the pre-[REDACTED] share incentive schemes (the “**Share Incentive Schemes**”). Under the Share Incentive Schemes, eligible participants were granted partnership interest in the Employee Incentive Platforms (the “**Incentive Awards**”). As of the Latest Practicable Date, our Employee Incentive Platforms, in aggregate, hold 20,000,000 Shares (taking into account the Share Subdivision), representing approximately 16.93% of our total issued Shares. For details of our Employee Incentive Platforms, see “History, Development and Corporate Structure — Employee Incentive Platforms.”

The Share Incentive Schemes do not involve any grant of share options or awards after the [REDACTED] and therefore is not subject to the provisions of Chapter 17 of the Listing Rules. Given the underlying Shares under the Share Incentive Schemes have already been issued, there will not be any further dilution effect to the issued Shares arising from the Share Incentive Schemes.

Below is a summary of the principal terms and provisions of Share Incentive Schemes.

(i) Purpose

The Share Incentive Schemes aim to attract and retain top-tier talent for key positions of significant responsibility, provide additional incentives to selected employees, and support the growth and success of our business. By granting the Incentive Awards, these plans offer eligible participants the opportunity to acquire or increase their proprietary interest in our Company, thereby aligning their interests with the long-term success of our Company.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

(ii) Eligible Participants

Persons eligible to participate in the Share Incentive Schemes include (i) senior management of our Company and its subsidiaries; (ii) middle management of our Company and its subsidiaries; (iii) core personnel of our Company and its subsidiaries; (iv) individuals who have made special contributions to our Company; (v) external consultants providing advisory services to our Company; and (vi) other individuals as approved by the Board.

(iii) Maximum number of Shares

The maximum number of Shares underlying the Incentive Awards that may be granted under the Share Incentive Schemes is 20,000,000. As of the date of this document, all Incentive Awards have been granted and vested to 31 grantees, including our senior management, counsels and employees, etc., and are subject to certain transfer and disposal restrictions pursuant to the partnership agreement. No further grants will be made under the Share Incentive Schemes following the [REDACTED].

(iv) Administration

Our Share Incentive Schemes are administered by Mr. Zhao, one of our Controlling Shareholders, who serves as the administrator under shareholder authority to determine all key issues including but not limited to the selection of grantees, the allocation of incentive awards represented by partnership interests in our Employee Incentive Platforms, Boda Innovation and Bohua Innovation — as well as the grant price and service period requirements.

E. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

2. Litigation

As of the Latest Practicable Date, we were not engaged in any litigation, arbitration or claim of material importance, and no litigation, arbitration or claim of material importance was known to our Directors to be pending or threatened by or against us, that would have a material adverse effect on our financial condition or results of operations.

3. Joint Sponsors

Our Company has entered into engagement agreements with the Joint Sponsors, pursuant to which our Company agreed to pay an aggregate of US\$650,000 (excluding expenses) to the Joint Sponsors to act as the sponsors to our Company in connection with the [REDACTED].

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

4. Preliminary Expenses

We did not incur any material preliminary expenses in relation to the incorporation of our Company.

5. Taxation of Holder of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty if such sale, purchase and transfer are effected on the H Share register of members of our Company, including in circumstances where such transaction is effected on the Stock Exchange. The current rate of Hong Kong stamp duty for such sale, purchase and transfer is 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred. For further information in relation to taxation, see “Appendix III — Taxation and Foreign Exchange.”

Potential [REDACTED] in the [REDACTED] are urged to consult their professional tax advisers if they are in any doubt as to the taxation implications of [REDACTED] for, purchasing, holding or disposing of or [REDACTED] in our H Shares (or exercising rights attached to them). None of our Company, our Directors, the Joint Sponsors, the [REDACTED], the [REDACTED], the [REDACTED], the [REDACTED], the [REDACTED], the [REDACTED], or any other person or party involved in the [REDACTED] accept responsibility for any tax effects on, or liabilities of, any person, resulting from the [REDACTED], purchase, holding or disposal of, [REDACTED] in or the exercise of any rights in relation to our H Shares.

6. Consents of Experts

The following experts have each given and have not withdrawn their respective written consents to the issue of this document with copies of their reports, letters, opinions or summaries of opinions (as the case may be) and the references to their names included herein in the form and context in which they are respectively included.

Name	Qualification
China Industrial Securities International Capital Limited	A corporation licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) of the regulated activities as defined under the SFO
ICBC International Capital Limited . . .	A licensed corporation to conduct Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities as defined under the SFO

APPENDIX VI STATUTORY AND GENERAL INFORMATION

Name	Qualification
KPMG	Certified Public Accountants Public Interest Entity Auditor registered in accordance with the Accounting and Financial Reporting Council Ordinance
Zhong Lun Law Firm	Legal advisors as to PRC laws
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Independent industry consultant

As of the Latest Practicable Date, none of the experts named above had any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

7. Promoters

The promoters of our Company are as follows:

No.	Name of promoters of our Company
1.	Mr. Zhao
2.	Boda Innovation
3.	Heda Big Health
4.	Bohua Innovation
5.	Zibo Xintaige Centennial Equity Investment Fund Partnership Enterprise (Limited Partnership) (淄博新太格百年股權投資基金 合夥企業(有限合夥))
6.	Suzhou Jinhe Phase III Equity Investment Partnership Enterprise (Limited Partnership) (蘇州金闔三期股權投資合夥企業(有限合 夥))
7.	Tibet Kaidesida Technology Industry (Group) Co., Ltd. (西藏凱 德思達科技產業(集團)有限公司)
8.	Mr. Zhao Liang (趙亮)
9.	Hangzhou Efung Runjun Venture Capital Partnership (杭州倚鋒 潤君創業投資合夥企業(有限合夥))
10.	Beijing Shunhe Dingsen Technology Development Co., Ltd. (北 京舜和鼎森科技發展有限公司)
11.	Shenzhen Kunchen Phase VI Venture Capital Partnership Enterprise (Limited Partnership) (深圳坤辰六期創業投資合夥企 業(有限合夥))

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Within the two years immediately preceding the date of this document, no cash, securities, amount or benefit has been paid, allotted or given, or has been proposed to be paid, allotted or given, to any of the promoters named above in connection with the [REDACTED] or the related transactions described in this document.

8. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

9. Binding Effect

This document shall have the effect, if an application is made in pursuance of this document, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of Sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance in so far as applicable.

10. No Material Adverse Change

Our Directors confirm that there has been no material adverse change in our financial, trading position or prospects since June 30, 2026, being the period end date of our latest consolidated financial statements as set out in “Appendix I — Accountants’ Report,” up to the date of this document.

11. Miscellaneous

In connection with the [REDACTED],

- (i) within the two years immediately preceding the date of this document:
 - (a) saved as disclosed in the “History, Development and Corporate Structure” section and “3. Changes in the Share Capital of Our Subsidiaries” above, no Share or loan capital of our Company or any of its subsidiaries has been issued nor agreed to be issued fully or partly paid either for cash or for a consideration other than cash; and
 - (b) saved as disclosed in the “[REDACTED]” section, no commissions, discounts, brokerage fee or other special terms have been granted in connection with the issue or sale of any Share or loan capital of our Company or any of our subsidiaries;
- (ii) no Share or loan capital of our Company is under option or is agreed conditionally or unconditionally to be put under option;

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (iii) there are no arrangements under which future dividends are waived or agreed to be waived;
- (iv) there are no procedures for the exercise of any right of pre-emption or transferability of subscription rights;
- (v) there have been no interruptions in our business which may have or have had a significant effect on our financial position in the last 12 months;
- (vi) no part of the equity or debt securities of our Company or any member of our Group, if any, is currently [REDACTED] on or [REDACTED] on any stock exchange or [REDACTED] system, and no such [REDACTED] or permission to [REDACTED] on any stock exchange other than the Hong Kong Stock Exchange is currently being or agreed to be sought; and
- (vii) our Company has no outstanding convertible debt securities or debentures.